1 November 2020 in Journal of Investigative Dermatology
19 December 2025 in Cancer Research
Tumor senescence is a critical mechanism underlying tumor progression and recurrence. A better understanding of how premetastatic circulating tumor cells (CTC) exploit senescence to survive in the bloodstream could help reveal vulnerabilities for therapeutic intervention. Using patient-derived melanoma CTC lines and xenograft models, we identified a role for the cytoskeletal regulator cortactin in mTOR/p53-dependent senescence. Cortactin localized to Rab7-positive endosomes and maintained late-endosomal homeostasis. Depletion of cortactin induced aberrant endosomal aggregates with mTOR accumulation and hyperactivation, subsequently leading to p53 activation, G0–G1 arrest, and cellular senescence. This oncogene-induced senescence was characterized by the induction of the senescence-associated secretory phenotype and β-galactosidase (SA-β-gal), loss of Ki-67 and lamin B1, and elevated mitochondrial reactive oxygen species (mtROS). Notably, a positive feedback loop between p53 and mtROS was essential for maintaining stable senescence in CTCs. Clinically, the proportion of SA-β-gal–positive senescent CTCs was significantly correlated with therapeutic resistance and disease progression in a prospective cohort of patients with melanoma. A sequential strategy using cortactin depletion followed by an anti–Bcl-xL senolytic eliminated the persistent CTCs and suppressed blood-borne metastasis. Thus, this study uncovered a unique senescent CTC subpopulation regulated by a cortactin/mTOR/p53/mtROS axis that can be targeted to suppress the metastatic progression of melanoma. Significance: The cytoskeleton regulator cortactin governs senescence induction and maintenance in melanoma circulating tumor cells, providing an axis that can be targeted by a sequential therapeutic strategy to block metastasis.
9 October 2025 in PLOS ONE
Background: Metastatic melanoma is a challenging clinical condition with poor prognosis. Recent research has highlighted the role of antibody-dependent cellular phagocytosis (ADCP) in tumor immunity, suggesting prognostic implications for ADCP-related genes (ARGs). This study develops a prognostic model for metastatic melanoma using ARGs to enhance clinical decision-making and therapeutic strategies. Methods: Prognostic ARGs were identified from the GSE46517 and GSE7553 datasets. A prognostic model was constructed using LASSO-Cox regression and validated across multiple cohorts, including TCGA and GEO datasets. A nomogram was developed to assess survival outcomes in metastatic melanoma patients. Functional assays, including siRNA knockdown of DOCK10 in A375 cells, were conducted to validate the role of DOCK10 in melanoma progression. Results: A prognostic model based on six ARGs—NDRG1, HRAS, KPNA2, ICAM1, DOCK10, and CDC20—was developed. Patients were stratified into high- and low-risk groups based on risk scores, with high-risk patients showing poorer overall survival (OS) in both validation cohorts. The model was validated as an independent prognostic factor. Gene set enrichment analysis (GSEA) indicated that the low-risk group was enriched in immune-related pathways. High-risk patients exhibited higher genomic instability, which was associated with poorer prognosis. Knockdown of DOCK10 in A375 cells significantly reduced proliferation, migration, and invasion, confirming its role in melanoma progression. Conclusion: The model also demonstrated associations with immune cell infiltration and drug sensitivity, highlighting its potential utility in optimizing immunotherapy and chemotherapy strategies. This study developed a novel ARG-based prognostic model that aids in survival prediction and therapeutic decision-making for metastatic melanoma patients. DOCK10 was identified as a potential therapeutic target in melanoma metastasis.